Advertisement
Advertisement
U.S. Markets close in 1 hr 23 mins
Advertisement
Advertisement
Advertisement
Advertisement

LeMaitre Vascular, Inc. (LMAT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
50.03+1.40 (+2.89%)
As of 02:34PM EST. Market open.
Advertisement
Sign in to post a message.
  • Y
    Yahoo Finance Insights
    LeMaitre Vascular is up 5.00% to 49.13
  • Y
    Yahoo Finance Insights
    LeMaitre Vascular is down 5.09% to 48.29
  • Y
    Yahoo Finance Insights
    LeMaitre Vascular is up 5.23% to 54.28
  • S
    StephenG
    LMAT is building to be a billion dollar market cap xenograph behemoth in vascular and renal arena:

    https://finance.yahoo.com/news/lemaitre-vascular-acquires-artegraft-201300565.html
  • Y
    Yahoo Finance Insights
    LeMaitre Vascular is up 5.15% to 54.74
  • A
    Aladdin
    Sounds like things are back on track and we should see new highs in the next 12mo. I find it hard to see no big Med Equip company making an offer, Buy away! MY calls should have a nice pop today :)
  • S
    StephenG
    Here is my investment thesis on LMAT. Currently going at $1.00+ earnings per share (last quarter $.25 annualized) for 2018, which will morph to easily $1.20+/Y for FY 2019. On medical technology that is growing... give that at least a 35X PE ratio - so mid 40's would be my 12 month forecast. Steady growth and upwards trajectory. No brainer to buy and sit, while getting a dividend.
  • 8
    8man
    Really what is going on? New competition ?
  • A
    Aladdin
    Shame no one really follows company.

    Thinly traded, good spot to be in but they really need to Sell to unlock bigger gain.
    Neutral
  • S
    StephenG
    Now that Conestoga Small Cap Fund has put at $40 floor on LMAT shares, the inane two million share shorts have to think of licking their wounds and move onto really worthy candidates. Why would anyone gamble this way with a dividend paying growth company in the Med-tech arena? As shorts panic and get further squeezed, look for LMAT to move to the mid $50’s especially after the Company will report surprise great quarterly results during this entire year.
    Bullish
  • S
    StephenG
    from a posting on Friday on StockTwits:
    "Short squeeze in progress with crazy proportion of shorts... who on earth shorts a dividend paying , undervalued, growth stock in the Med-tech field??? how in inane. No supply of shares with almost 90% held by institutions. Watch for growth in profits, revenues, sales forces, meaty acquisitions and more global approvals for their bag of products. Perfect waves for each quarterly report for the next 3 years will bring upwards surprises as trends now begin to snowball and accumulate with big progress in each metric. Certainly in the 70's by YE, and over $100 in the follow YE 2022."
    Bullish
  • M
    Michael
    "....well I heard it through the grape vine." LMAT is on someone's radar screen. A 'good' Bio Med opportunity for this Burlington, MA gem....
  • S
    StephenG
    Great quarter and surprising guidance. Organic growth coming back over the months of the third quarter. Looks like earnings can be around $1.50 for 2021... with some surprise larger acquisitions very possible. Shares should be nearing $50 in a year, higher dividends and growth both thru existing products and newly acquired. The company is now enjoying the bio revolution as nearly 50% of their revenue is biological (allographs & xenographs). Very well managed during this Covid crisis with a focus on profits and rolling up this sector. This can be explosive especially with 2 million shares short which is totally inane. Who on earth shorts a growth, profitable, dividend paying company in the MedTech field? Squeeze during a period of growth in the company's fortunes.
  • M
    Morton
    Nice quarter
    One upgrade so far:
    Barrington Research OUTPERFORM $36 -> $46
    Bullish
  • r
    rajm
    earning and sales beat according to Zacks number, let's see what happen tomorrow.
    guidance is also good.
  • B
    Bruce
    so what's going on, why down 25%
  • m
    mike27
    new acquisition for lmat. Should help earnings and share price down the road.
  • S
    StephenG
    It seems that LMAT divested its general surgery product lines for $7.4 million to clear the deck for a big acquisition within the vascular arena, as they really do not need the cash otherwise. IMHO.. going north of $50 with the right deal that shows growth.
  • Y
    Yahoo Finance Insights
    LeMaitre Vascular is up 10.58% to 31.99
Advertisement
Advertisement